Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Hypopharyngeal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
11 drugs · 52 active trials
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cisplatin | Phase 3 | Phase 3 | 13 | 8 | 9 | 41 | 0 | — | — | Dec 15, 2001 |
| Pembrolizumab | Phase 3 | Phase 3 | 10 | 5 | 2 | 12 | 0 | — | — | 2015-11 |
| Carboplatin | Phase 3 | Phase 3 | 9 | 3 | 4 | 16 | 0 | — | — | Apr 25, 2007 |
| Paclitaxel | Phase 3 | Phase 3 | 6 | 2 | 2 | 10 | 0 | — | — | Apr 25, 2007 |
| Cetuximab | Phase 3 | Phase 3 | 5 | 4 | 7 | 24 | 0 | — | — | 2005-01 |
| Docetaxel | Phase 3 | Phase 3 | 3 | 1 | 5 | 13 | 0 | — | — | Dec 15, 2001 |
| Fluorouracil | Phase 3 | Phase 3 | 2 | 0 | 3 | 7 | 0 | — | — | 2001-07 |
| Bevacizumab | Phase 3 | Phase 3 | 2 | 0 | 2 | 6 | 0 | — | — | 2001-07 |
| Atezolizumab | Phase 3 | Phase 3 | 1 | 0 | 2 | 2 | 0 | — | — | Mar 22, 2013 |
| Tretinoin | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Feb 20, 2025 |
| Durvalumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Apr 3, 2018 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Nov 30, 2021 |
| Toripalimab | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Apr 7, 2021 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Sep 18, 2018 |
| Ipatasertib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 26, 2022 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 1 | 1 | 0 | 13 | 0 | — | — | 2001-12 |
| Capecitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2009-10 |
| Nivolumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Nov 13, 2017 |
| Celecoxib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 27, 2019 |
| Methotrexate | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 9, 2025 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 2, 2025 |
| Sorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 25, 2007 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2010-12 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-05 |
| Camrelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 21, 2020 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-12 |
| Sunitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-07 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-02 |
| Dasatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-07 |
| Dexamethasone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-02 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-06 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| Berzosertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 17, 2017 |
| Camonsertib | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 13, 2027 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 6, 2022 |
| Everolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-11 |
| Gefitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-02 |
| Hydroxyurea | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-07 |
| Adavosertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 22, 2017 |
| Alvespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| Filgrastim | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-07 |
| Ganetespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-12 |
| Ipilimumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 9, 2013 |
| Lenalidomide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 10, 2011 |
| Nab-paclitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 26, 2013 |
| Onalespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 22, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.